Pfizer CEO expresses optimism on RFK Jr.'s HHS nomination

Pfizer CEO Albert Bourla has expressed cautious optimism about working with Robert F. Kennedy Jr., President Donald Trump's nominee to lead the Department of Health and Human Services (HHS), despite Kennedy's historical anti-vaccine stance. Bourla noted that Kennedy has moderated his views in recent hearings and discussions, suggesting potential for collaboration on issues like cancer treatment and chronic diseases. Bourla believes Kennedy's influence would not extend to removing vaccine liability protections, which require Senate approval, and expects strong opposition from the medical community should Kennedy attempt to undermine vaccine programs. The Senate Finance Committee has advanced Kennedy's nomination, indicating likely confirmation. Bourla and other industry leaders have met with Kennedy and Trump, finding his views less radical than publicly perceived. This development comes amid Pfizer's strong financial performance, reporting a 17% increase in fourth-quarter revenue.